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Abstract 19 
Monoacylglycerol lipase (MAGL) is a membrane-associated cytosolic serine hydrolase 20 
which catalyses the hydrolysis of the endocannabinoid 2-arachidonoylglycerol into 21 
arachidonic acid and glycerol. MAGL represents the link between the endocannabinoid and 22 
the eicosanoid system indeed its inhibition enhances endocannabinoid signalling and lowers 23 
eicosanoid production. Here we present a radioactive-free, sensitive and solid HPLC-UV 24 
based method to evaluate MAGL activity by using 4-nitrophenylacetate (4-NPA) as substrate. 25 
The enzymatic activity is measured by quantifying the 4-nitrophenol (PNP) (=315 nm) 26 
formation on a C18 stationary phase. The method was validated by calculating IC50 values of 27 
the reference inhibitors JZL184, CAY10499 and JW642 and confirming the irreversible and 28 
non-competitive mechanism of inhibition for JZL184. Furthermore in order to resemble the 29 
catalytic conditions of MAGL at cell membrane level, the surfactant Triton® X-100 was 30 
added, as a micelle forming agent and 4-nitrophenyldodecanoate (4-NPDo) was used as 31 
lipophilic substrate for MAGL. The data obtained confirmed that the HPLC method is an 32 
alternative, radioactive-free approach for the screening and characterization of new MAGL 33 
inhibitors. Finally this assay prevents, in an unequivocal manner, any interference related to 34 
the intrinsic absorbance of screened compounds or metabolites generated upon enzymatic 35 
cleavage which could seriously affect the assay readout. 36 
 37 
 38 
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1. Introduction 42 
Monoacylglycerol lipase (MAGL) is a membrane-associated cytosolic serine hydrolase 43 
with the highest expression levels in the brain, white adipose tissue and liver [1]. MAGL 44 
catalyses the hydrolysis of monoacylglycerols into fatty acids and glycerol and the 45 
endocannabinoid 2-arachidonoylglycerol (2-AG) is one of its main substrates [2,3]. 2-AG is a 46 
lipid messenger which is synthesized on-demand from membrane phospholipid precursors 47 
and acts primarily by binding to cannabinoid G protein-coupled receptors (CB1R and CB2R). 48 
Recently it has also been shown that 2-AG can directly modulate GABA(A) receptor by 49 
behaving as a positive allosteric modulator [4]. In the brain, MAGL is responsible for about 50 
80% of the hydrolysis of 2-AG while the remaining 20% occurs mainly from the activity of 51 
other two serine hydrolases, α,β-hydrolase-6 (ABHD-6) and -12 (ABHD-12) [5,6]. The 52 
pharmacological inhibition of MAGL activity in vivo leads to a strong accumulation of 2-AG, 53 
in particular in the brain which triggers a higher activation of CB1R and CB2R resulting in 54 
analgesic, anxiolytic, antidepressant, sleep-inducing and anti-inflammatory effects [7-10]. 55 
Recently, it has been shown that in some tissues, such as brain, liver and lung, 2-AG acts as a 56 
precursor for the arachidonic acid production [1]. Arachidonic acid is mainly oxygenated by 57 
cyclooxygenase-2 to generate pro-inflammatory eicosanoids such as prostaglandin-E2 and 58 
prostaglandin–D2. Therefore, the analgesic and anti-inflammatory effects induced by MAGL 59 
inhibition can be dependent on two underlying mechanisms, the first by directly increasing 2-60 
AG levels and the second by lowering the arachidonic acid formation as previously described 61 
in brain [1]. Thus, MAGL could represent the link between two lipid signaling pathways: the 62 
endocannabinoid and the eicosanoid systems [11]. The modulation of MAGL activity can 63 
lead to several beneficial effects through either enhancing the tone of the endocannabinoid 64 
system or lowering eicosanoids production. Therefore, MAGL inhibitors may represent an 65 
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attractive therapeutic approach for the treatment of pain, inflammation, [12-15], anxiety 66 
[16,17], neurodegeneration [3,18,19], cancer [1,20] and other disorders [7-9].  67 
Conventional assays to investigate the inhibition of MAGL employ the radioactive 68 
substrates [3H]-2-AG or [3H]-2-oleoyl glycerol (2-OG) [21-26], as well as the analytical 69 
determination of the arachidonic acid formation from 2-AG hydrolysis quantified by high-70 
performance liquid chromatography (HPLC), mass spectrometry [6,27-29] or ultraviolet light 71 
(UV) [30,31]. Recently, a colorimetric assay that exploits 4-nitrophenylacetate (4-NPA) as 72 
non-specific chromogenic substrate for MAGL activity has been described [32]. In this assay, 73 
4-NPA releases, upon hydrolysis, 4-nitrophenol (PNP), whose absorbance is measured at 405 74 
nm. Thus, by quantifying the amount of absorbance, the assay enables monitoring the degree 75 
of MAGL activity. In addition, HPLC fluorescence assays have been developed exploiting 7-76 
hydroxycoumarinyl arachidonate (7-HCA) [33] or 1,3-dihydroxypropan-2-yl 4-pyren-1-77 
ylbutanoate [34] as substrates. In these two assays, the hydrolytic activity of MAGL is 78 
evaluated by the fluorimetric detection of 7-hydroxyl coumarin or 4-pyren-1-ylbutanoic acid 79 
formation, respectively. 80 
In the present work, we show an alternative radioactive-free, sensitive and accurate 81 
HPLC-UV based method to evaluate MAGL activity and test new inhibitors. The assay is 82 
based on the chromatographic separation and subsequent absorbance measurement of PNP, 83 
that is formed upon hydrolysis of 4-NPA. This method (4-NPA method) enables measuring 84 
the PNP formation at the optimal wavelength of 315 nm avoiding the potential interference of 85 
any residual, non-cleaved 4-NPA which still exhibits a significant absorbance at such 86 
wavelength. Furthermore, the chromatographic separation of PNP before measuring the 87 
absorbance, prevents any interference in the assay readout potentially generated by coloured 88 
or fluorescent compounds. This allows to safely evaluate the inhibition of MAGL activity by 89 
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molecules which possess intrinsic absorbance property, that is for example a typical feature 90 
of many natural products. 91 
We also investigated the validity of this method under different assay conditions that 92 
resemble the cellular environment of MAGL activity. The crystal structure of MAGL was 93 
recently resolved and it provided evidence that the catalytic activity occurs at the interface 94 
between the inner leaflet of the plasma membrane and the cytosol. First, the enzyme 95 
“recruits” the lipophilic substrates (e.g., 2-AG) from the membrane and then moves them to 96 
the active site where the hydrolysis takes place [35]. In order to reproduce in vitro this 97 
condition, we decided to perform additional experiments where the substrate is presented to 98 
the enzyme in a lipid/water interface. This was achieved through the addition of the 99 
surfactant Triton® X-100, as a micelle forming agent, in the assay buffer [34] and using the 100 
more lipophilic substrate, 4-nitrophenyldodecanoate (4-NPDo), whose hydrolysis generates 101 
PNP (4-NPDo/TX method). Although it is not specifically reported that MAGL can 102 
hydrolyse 4-NPDo, the latter is a well-known substrate for many other lipases.  103 
 104 
2. Material and Methods 105 
2.1 Chemicals and reagents 106 
4-Nitrophenylacetate (4-NPA), 4-Nitrophenyldodecanoate (4-NPDo), 4-nitrophenol 107 
(PNP), Tris(hydroxymethyl)aminomethane (Tris base), Ethylenediaminetetraacetic acid 108 
(EDTA), Triton X-100, gradient grade solvents, acetonitrile (ACN) and methanol (MeOH), 109 
absolute ethanol, dimethylsulfoxide (DMSO), acetic acid and ammonium acetate for HPLC 110 
were purchased from Sigma-Aldrich. Benzyl [4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3(2H)-111 
yl]-2-methylphenyl)carbamate (CAY10499), 4-[Bis(1,3-benzodioxol-5-yl)hydroxymethyl]-1-112 
piperidinecarboxylic acid 4-nitrophenyl ester (JZL184), 1,1,1,3,3,3-hexafluoropropan-2-yl-4-113 
(3-phenoxybenzyl)piperazine-1-carboxylate (JW642), N-Methyl-N-[[3-(4-114 
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pyridinyl)phenyl]methyl]-4'-(aminocarbonyl)[1,1'-biphenyl]-4-yl carbamic acid ester 115 
(WWL70), (3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl)-cyclohexylcarbamate (URB597) and 116 
human recombinant MAGL (hrMAGL) were purchased from Cayman Chemicals. 117 
CAY10499, JZL184, JW642 WWL70 and URB597 stock solutions were prepared in DMSO 118 
or ethanol (according to Cayman product information) and then diluted in absolute ethanol in 119 
order to reach the desired concentration. 120 
 121 
2.2 HPLC-UV chromatographic conditions 122 
A Thermo Finnigan HPLC system was used to quantify PNP formed after enzymatic 123 
hydrolysis of both 4-NPA and 4-NPDo. The HPLC system consists of a Thermo Finnigan 124 
SpectraSystem SN4000 system controller, coupled with P2000 pump, a SCM1000 degasser 125 
and a UV2000 UV detector at operation wavelength of 270 nm (4-NPA and 4-NPDo) and 126 
315 nm (PNP). Data were monitored and analyzed using ChromQuest software (Thermo 127 
Finnigan, Waltham, MA, USA). Separation of compounds was carried out at ambient 128 
temperature on to reverse-phase column (150 x 4.6 mm; 5 µm). The mobile phase, delivered 129 
at a flow rate of 1.0 ml/min, consists of methanol and ammonium acetate buffer (pH 4.0; 10 130 
mM,) (53:47, v/v) for 4-NPA and PNP separation. For 4-NPDo and PNP separation, gradient 131 
conditions were used; solvent A was ACN and solvent B was ammonium acetate buffer (pH 132 
4.0; 10 mM). Gradient conditions at a flow rate of 1.0 ml/min were as follows: 0-3 min linear 133 
gradient from 40% to 90% of A; 3-20 min. 90% of A. Ammonium acetate buffer was filtered 134 
through a 0.45 μm membrane before use. The sample injection volume was 20 l. 135 
 136 
2.3 Substrate stability 137 
4-NPA stability was tested preparing a 4.25 mM solution in DMSO, Tris-HCl buffer (pH 138 
= 7.2; 10 mM containing 1.0 mM EDTA) or absolute ethanol and they were stored at room 139 
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temperature, 3 °C or -20 °C. Samples analysis was performed by diluting 10 µl of each stock 140 
solution in 170 µl of water and monitoring 4-NPA and PNP concentrations by HPLC after 5 141 
h and 48 h.  142 
4-NPDo stability was tested preparing a 486 μM solution in ACN in the same conditions 143 
above reported for 4-NPA.  144 
 145 
2.4 Surface tension measurements 146 
The measurements of surface tension for a concentration series of Triton® X-100 147 
surfactant in Tris-HCl buffer solutions were performed using a DuNuoy tensiometer (K6, 148 
Kruss, Germany) equipped with a platinum ring (mean ring radius 9.545 mm and wire radius 149 
0.185 mm). The surfactant concentrations analysed for buffer solution ranged between 0.3000 150 
and 0.0005 % w/w and three replicates were carried out for each measurement.  151 
 152 
2.5 HPLC-UV assay  153 
For 4-NPA method, an aliquot of stock solutions of hrMAGL (10 μg/50 μl) was diluted 154 
1:125 with Tris-HCl buffer (pH = 7.2; 10 mM, containing 1.0 mM EDTA) to obtain the 155 
working solutions of hrMAGL at 1.6 ng/μl. The stock and working solutions were stored at 156 
−20 °C. 157 
In a 0.5 ml spin tube containing 75 μl of Tris-HCl buffer (pH= 7.2; 10 mM containing 1.0 158 
mM EDTA), 5 l of working solution hrMAGL (8 ng), 5 l inhibitor (or solvent as control) 159 
were added. Samples were pre-incubated for 30 minutes at 37 °C and then 5 l of a solution 160 
of 4-NPA in absolute ethanol (4.25 mM) were added. Samples were incubated for 10 minutes 161 
at 37 °C. The enzymatic reaction was stopped by cooling in an ice bath for 10 minutes and 162 
then 20 l of the reaction mixture were taken and analysed by HPLC.  163 
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The evaluation of the initial velocity was carried out by incubating the samples at 37 °C at 164 
different times (0, 5, 15, 25, 35, and 45 minutes). In the reversibility assay a rapid 1:10 165 
dilution of the pre-incubated mixture was performed before adding 4-NPA. Then, the reaction 166 
mixture was incubated at 37 °C for 10, 30 and 60 min. before quantifying PNP formation. 167 
The competition assay was performed by adding different concentrations of substrate 168 
(ranging from 0.05 to 4 mM) to the pre-incubated mixture and the enzyme activity was 169 
evaluated after 10 minutes at 37 °C.  170 
Kinetics parameters (Km and Vmax) were calculated according to a procedure previously 171 
reported [32]. In a 0.5 ml spin tube containing 80 μL of Tris-HCl buffer (10 mM, pH = 7.2, 172 
containing 1.0 mM EDTA), 5 μL of working solution of hrMAGL (8 ng) and 5 μL of the 173 
proper solution of 4-NPA in ethanol (55 μM to 5000 μM) were added. Samples were 174 
incubated for 10 minutes at 37 °C and analysed by HPLC. 175 
For 4-NPDo/TX method, an aliquot of a solution of hrMAGL (0.19 μg/μl) was diluted 176 
1:120 with Tris-HCl buffer (pH = 7.2 10 mM containing 1 mM EDTA). In a 0.5 mL spin tube 177 
containing 80 μl of Tris-HCl buffer (10 mM, pH 7.2, containing 1.0 mM EDTA and 0.2 % 178 
(m/v) Triton® X-100), 5 µl of a solution of inhibitor (or solvent in case of the controls) and 5 179 
µL of a solution of 4-NPDo in ACN (486 μM) were added. The mixture was pre-incubated 180 
for 10 minutes at 37 °C and then the enzymatic reaction was started by adding of 5 µL of the 181 
working solution of hrMAGL and continued for 30 min. at 37 °C. The final incubation 182 
volume of 90 µL contained 27 µM of the substrate and 8 ng of MAGL. The enzymatic 183 
reaction was stopped by cooling in ice bath and then 20 μl of the reaction solution were 184 
analyzed by HPLC.  185 
Kinetics parameters (Km and Vmax) were calculated. First, regression progress curves of 186 
enzymatic reaction were obtained for different substrate concentrations (from 25 μM to 250 187 
μM). In a 0.5 ml spin tube containing 80 μl of Tris-HCl buffer (pH 7.2, 10 mM, containing 188 
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1.0 mM EDTA and 0.2 % (m/v) Triton® X-100) 5 µl of the proper solution of 4-NPDo were 189 
added. Samples were pre-incubated for 10 minutes at 37 °C and then 5 µL of the working 190 
solution of hrMAGL (8 ng) were added. After further incubation at 37 °C for various times 191 
(from 0 to 55 minutes), 20 μl of the reaction solution were analyzed by HPLC. The product 192 
generated (PNP) was plotted versus times (X-axis) to generate the reaction progress curves 193 
for each substrate concentration.  194 
Initial velocity (vo) for each regression progress curve is equivalent to the slope of the 195 
linear portion of the curve and it was calculated using linear regression method. Then, the 196 
resulting slope (initial velocity) for each of the reaction progress curves were plotted on the 197 
Y-axis against the concentration of substrate (X-axis) by a nonlinear regression analysis, 198 
using a rectangular hyperbola model to evaluate Km and Vmax using 4-NPDo as MAGL 199 
substrate.  200 
 201 
2.6 Chromatographic method validation 202 
Calibration curve for 4-NPA and PNP were built by analysing triplicate of eight 203 
concentrations for each substance (from 250 M to 0.25 M for PNP, from 125 M to 25 M 204 
for 4-NPA). Since the separation of 4-NPDo and PNP has required novel chromatographic 205 
conditions, the calibration curve for both the analytes was evaluated by analysing triplicate of 206 
eight concentrations for each substance (from 125 M to 0.25 M). Limit of detection and 207 
quantification were also evaluated.  208 
Least squares regression parameters for the calibration curve were calculated, and the 209 
concentrations of the test samples were interpolated from the regression parameters. Sample 210 
concentrations were determined by linear regression, using the formula Y=mX+b, where 211 
Y=peak area, X=concentration of the standard in nanograms per millilitre, m=the slope of the 212 
curve and b=the intercept with y-axis. Correlation coefficients for each of the calibration 213 
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curves were >0.99. Accuracy and intermediate precision were determined on different 214 
analytes concentration levels: low (250 and 10.0 M), medium (750 and 50 M) and high 215 
QC (2000 and 100 M) for 4-NPA, 4-NPDo and PNP, respectively. Accuracy and within-run 216 
and between-run precision were assessed on quality control samples (QC samples) and 217 
determined by replicate analysis using seven determinations of different concentration levels: 218 
low (0.5 mM), medium (50 mM) and high (100 mM) (Table 1). 219 
For accuracy five replicates of each concentration was analysed during the same 220 
analytical session. Intermediate precision was tested analysing triplicates of each 221 
concentration in three different days. 222 
 223 
2.7 Method validation 224 
MAGL initial velocity was evaluated in order to define the best incubation time at 37 °C. 225 
Km and Vmax values of hrMAGL for 4-NPA and for 4-NPDo were evaluated to ensure a good 226 
precision of the method. For 4-NPA method, MAGL reference inhibitors CAY10499, 227 
JZL184 and JW642 were screened at 1 μM as well as WWL70, URB597 as negative 228 
controls. Applicability of the method was tested calculating the IC50 values of MAGL 229 
inhibitors and characterizing the JZL184 mechanism of inhibition. Inhibition curve 230 
experiments were performed evaluating a minimum of six different concentrations of each 231 
compound ranging from 1 μM to 67 pM for JZL184, from 7 μM to 0.7 nM for JW642 and 232 
from 5 μM to 50 pM for CAY10499. Data were collected from two independent experiments 233 
performed in triplicates. 234 
In the case of 4-NPDo/TX method, JW642 and JZL184 were screened evaluating a 235 
minimum of six different concentrations from 1 nM to 150 μM. 236 
 237 
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2.8 Radiometric hrMAGL assay 238 
hrMAGL esterase activity was assessed as previously reported [36]. The reaction 239 
consisted of 196 µl assay buffer (pH 7.4, 10 mM Tris-HCl, 1 mM EDTA, plus 0.1% fatty 240 
acid-free BSA) containing 25 ng of hrMAGL and 2 µl of JZL184, CAY10499, JW642 or 241 
vehicle. The mixture was incubated for 30 min at 37 °C and afterwards, 1.5 nM of [3H]-2-242 
oleoylglycerol ([3H]-2OG) (2 µl) were added. The solution was further incubated for 20 min. 243 
at 37 °C and the reaction was stopped by adding 400 µl of chloroform:methanol mixture (1:1, 244 
v/v). Tubes were vortexed and centrifuged for 10 min. at 10 000 x g at 4 °C. Finally, the 245 
upper aqueous phase was transferred in scintillation tubes and mixed with 3 ml of Ultima 246 
Gold scintillation liquid (PerkinElmer Life Sciences). Radioactivity was measured using a 247 
Beckman LS6500 scintillation counter. Data were collected from two independent 248 
experiments performed in triplicates and the results were expressed as % [3H]-glycerol 249 
formation, relative to that in vehicle-treated samples (=100%). 250 
 251 
2.9 Data analysis 252 
Results are expressed as mean values ± S.D. for each examined group. Statistical 253 
significance of differences between groups was determined by the Student’s t-test (paired t-254 
test) with GraphPad Prism 5 software (GraphPad Software Inc., San Diego, CA, USA). 255 
Statistical differences between treated and vehicle control groups were determined by 256 
Student’s t-test for dependent samples. Differences between the analysed samples were 257 
considered as significant if p≤0.05. 258 
 259 
3. Results 260 
3.1. Chromatographic conditions optimization and validation 261 
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In order to assess MAGL activity by HLPC, we checked the chromatographic conditions 262 
to detect and quantify the hydrolytic product PNP from 4-NPA or from 4-NPDo (Fig. 1). A 263 
C18 stationary phase was used to perform resolution of analytes eluting with different 264 
mixture of methanol and ammonium acetate buffer for 4-NPA or ACN and ammonium 265 
acetate buffer for 4-NPDo. Different pH buffers (7, 6, 5 and 4) were tested obtaining a best 266 
resolution at acid pH due to the undissociated form of the PNP. A diode-array detector was 267 
used to record UV-visible spectra of each analytes at pH = 7 (pH condition for colorimetric 268 
assay) and pH = 4 (pH condition for chromatographic assay) highlighting a maximum 269 
absorbance at 270 nm for 4-NPA and 4-NPDo and at 315 nm for PNP (Fig. 2). UV-VIS 270 
spectra comparison showed a greater absorbance of PNP at the selected wavelength (315 nm) 271 
than that used for the colorimetric assay (405 nm) in both pH conditions. Method linearity 272 
was assessed by performing calibration curves of PNP. Quantification of PNP was performed 273 
at 315 nm. The calculated coefficient of determination for linear regression (R2) was 0.999 274 
for 4-NPA method and 0.998 for 4-NPDo/TX method and limit of quantification (LOQ) and 275 
detection (LOD) were 0.50 μM and 0.25 μM respectively for both methods. 276 
 277 
3.2 Determination of critical micelle concentration (CMC) 278 
The data obtained from surface tension measurements showed typical curves of 279 
surfactants, (Triton® X-100), i.e. in the first part the surface tension depends linearly on the 280 
logarithm of the concentration up to CMC; above this value it becomes independent of the 281 
concentration forming a plateau. The CMC was determined from the intersection between the 282 
regression straight line of the linearly dependent region and the straight line describing the 283 
plateau. The CMC value determined for surfactant solution was 0.0190 % w/w in Tris-HCl 284 
buffer.  285 
 286 
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3.3 Substrate stability 287 
4-NPA stability was assessed in different solvents commonly used in biological assays, 288 
such as DMSO, ethanol and Tris-HCl buffer, with the latter also used for hrMAGL dilution. 289 
Different temperatures were tested to evaluate the best conditions for stock solution storage 290 
and substrate stability during the assay execution. Spontaneous hydrolysis was observed at 291 
room temperature and 3 °C in all the solvents excepted for the absolute ethanol which 292 
showed a negligible degradation at r.t. and 3 °C (Table 2). DMSO solutions stored at 3 °C, 293 
showed higher degradation of 4-NPA than the sample stored at r.t.. Such effect is probably a 294 
consequence of the freezing and thawing cycle of the DMSO solution which can enhance 295 
substrate degradation. For longer storage periods, the best conditions are represented by 296 
absolute ethanol as solvent and -20 °C as temperature (Table 2). Those conditions ensure a 297 
standard stability of the substrate for at least two months.  298 
4-NPDo stability was tested in ACN in the same conditions above reported for 4-NPA. 299 
This substrate showed a negligible degradation at all different tested conditions (data not 300 
showed).  301 
In every experiment a background analysis (without enzyme) of the spontaneous, non-302 
specific cleavage of the substrate was included and it was always subtracted. 303 
 304 
3.4 Method optimization and validation 305 
In order to optimize the HPLC-UV based assay, the initial velocity of MAGL activity was 306 
evaluated for the two substrates (4-NPA and 4-NPDo) in order to define the reaction kinetics 307 
of both conditions. In case of 4-NPA, the data obtained showed that the rate of hydrolysis is 308 
linear in the first 20 minutes of incubation at 37 °C, therefore 10 minutes was chosen for 309 
testing the inhibitors. 310 
14 
 
Conversely, for 4-NPDo/TX method, a preincubation time of 10 min. of substrate and 311 
inhibitor in Tris-HCl buffer was chosen accordingly to that reported for a similar method 312 
using Triton® X-100 as a micelle forming agent [34]. Then the enzymatic reaction was 313 
started, the incubation was continued for 30 min., nevertheless kinetic experiments showed 314 
that the rate of hydrolysis is linear within the first 20 minutes. Because many inhibitors of 315 
MAGL act by forming covalent bonds with the enzyme, a somewhat longer incubation period 316 
was chosen to give the inhibitors enough time to exert their full activity. 317 
In order to validate our assay, we calculated the Michaelis-Menten constant (Km) and Vmax 318 
for the enzymatic reaction, obtaining values corresponding to 0.50 ± 0.06 mM and 30.83 ± 319 
1.29 μmol min-1 mg-1, respectively for 4-NPA method. These parameters are in agreement 320 
with literature for the evaluation of MAGL activity carried out by exploiting the same 4-321 
NPA/PNP principle in the colorimetric assay (Km: 0.2 ± 0.05 mM and Vmax: 52.2 ± 2.3 μmol 322 
min-1 mg-1) [32]. 323 
In the case of 4-NPDo/TX method, the Km and Vmax values were 27 ± 1.3 μM and 1.2 ± 324 
0.11 μmol min-1 mg-1 respectively, suggesting a more efficient enzymatic activity. 325 
The 4-NPA method was further validated by testing the effect of conventional well 326 
characterized MAGL inhibitors such as JZL184, CAY10499 and JW642. As negative 327 
controls, the selective fatty acid amide hydrolase inhibitor URB597 and the ABHD-6 328 
inhibitor WWL70 were also included. In a first attempt experiments were carried out at 329 
different pre-incubation times (from 0 to 30 min). The data confirmed a variability of JZL184 330 
inhibitory activity at different times of pre-incubation as previously reported in literature 331 
[37]. As shown in Fig. 3 JZL184 exerted its maximal inhibition as early as after 20 min. of 332 
pre-incubation. A pre-incubation time of 30 min. was further applied to screen all the 333 
inhibitors which were initially tested at 1 μM. The results confirmed the strong inhibitory 334 
activity of JZL184, CAY10499 and JW642 and the inactivity of URB597 and WWL70 (Fig. 335 
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4). The method was further validated by building concentration-dependent inhibition curves 336 
for JZL184, CAY10499 and JW642 which showed IC50 values of 24.17 ± 1.16 nM, 216.0 ± 337 
2.66 nM and 7.43 ± 1.08 nM, respectively. The data were compared with IC50 values 338 
obtained by performing the classic radiometric assay. As shown in Table 3, no significant 339 
differences were observed among the two sets of values. IC50 values of JW642 are fully in 340 
agreement with literature [38], while the values calculated for CAY10499 are slightly, but 341 
likely not significantly lower than the one reported in literature [32]. IC50 values of JZL184 342 
are fully in agreement with literature for both methods since it was already reported that 343 
JZL184 shows a reduced potency to inhibit MAGL activity when this was assessed by the 344 
colorimetric 4NPA/PNP method compared to the radioactive-based assay [37]. 345 
The 4-NPA method was also tested whether it would be suitable for characterizing the 346 
mechanism of enzymatic inhibition (reversibility and competitiveness). JZL184 was selected 347 
as reference compound. Reversibility assays were performed by a 10x dilution of the pre-348 
incubated samples before adding 4-NPA and the recovery of hrMAGL activity over time was 349 
monitored. The results confirmed the stability of the covalent interaction enzyme-JZL184 350 
highlighting an irreversible mode of inhibition (Fig. 5), according to literature [29].  351 
Michelis-Menten kinetics assay was used to confirm the non-competitive interaction of 352 
JZL184 with the enzyme. The results showed a decrease in the Vmax (61.42 ± 5.9 μmol min-1 353 
mg-1 and 44.41 ± 4.3 μmol min-1 mg-1 for control and JZL184, respectively) but no changes in 354 
the Km values upon JZL184 treatment (1.08 ± 0.26 mM and 1.47 ± 0.36 mM for control and 355 
JZL184, respectively) (Fig. 6). Thus, those data confirmed the non-competitive behaviour of 356 
this compound in hrMAGL inhibition [29]. 357 
In case of the 4-NPDo/TX method, JW642 and JZL184 were used as positive controls for 358 
MAGL inhibition and they showed IC50 values of 107.54 ± 11.3 nM and 145.67 ± 12.5 nM, 359 
respectively. In comparison with the 4-NPA method, the inhibitors showed a slight loss of 360 
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potency as it was also reported for a similar method using Triton® X-100 as micelle forming 361 
agent [34]. 362 
 363 
4. Discussion 364 
MAGL is the main hydrolytic enzyme for 2-AG and exerts a tight control of the 365 
endogenous levels of this lipid mediator. Many lines of evidence showed that inhibition of 366 
MAGL leads to a massive increase of 2-AG especially in the brain [9]. Recently, other two 367 
enzymes, ABHD-6 and -12 have been identified as hydrolytic enzymes for 2-AG [5, 6]. Their 368 
contribution on the total 2-AG cleavage can be mild (up to 20%) in case of the simultaneous 369 
presence of MAGL (like in neurons) or very consistent in case of the absence of MAGL, as it 370 
has been recently described for certain lines of macrophage [39]. Therefore, it is of high 371 
importance to characterize 2-AG hydrolysis inhibitors for the impact on the single enzymes 372 
involved in such process. The commonly used assays to evaluate 2-AG hydrolysis are based 373 
on radiolabelled isotope substrate, bulky fluorescent substrate or by using very sensitive and 374 
expensive analytical methods (i.e. LC-MS) which are not perfectly suitable for screening 375 
purposes. Few years ago a quick and cheap assay for the detection of MAGL activity by 376 
using 4-NPA as substrate was developed [32]. In the assay 4-NPA is hydrolysed and releases 377 
4-nitrophenol (PNP), which has an absorption in the UV-visible range (as well as a lot of 378 
nitro derivatives), thus making the test suitable to perform medium throughput screening for 379 
MAGL inhibitors in 96 and 384-well plate format. Despite the assay is easy to perform, the 380 
sensitivity of the detection is not optimal due to the range of wavelength (405-415 nm) used 381 
to quantify PNP formation. In fact, the optimum UV-visible absorption peak for PNP is at 382 
λ=315 nm with only a low absorption at λ≥400 nm (see Fig. 2). Changing the wavelength of 383 
detection would raise another experimental issue because the non-cleaved 4-NPA, which has 384 
an absorption peak at λ=270 nm, still exhibits a significant absorption in the range of 300-320 385 
17 
 
nm thus potentially interfering with the quantification of the hydrolytic product PNP (see Fig. 386 
2). 387 
Here we describe an implemented version of the 4-NPA/PNP assay by applying a HPLC 388 
separation step before quantifying the absorbance of the hydrolytic product. The use of the 389 
chromatographic system combined with an optimal UV-visible wavelength ensures a high 390 
sensitivity and specificity of the PNP detection as well as a significant reproducibility and 391 
accuracy of the results as confirmed by the data obtained testing different MAGL inhibitors 392 
(see Table 3). The chromatographic separation of the hydrolytic product from the rest of the 393 
reaction mixture before performing the absorbance measurement ensures that PNP can be 394 
quantified at its optimal wavelength of absorption (315 nm) preventing any potential 395 
interference of some residual, non-cleaved 4-NPA. The 4-NPA method was validated in 396 
comparison to the benchmark radioactive-based assay currently used to evaluate MAGL 397 
activity. The IC50 values calculated for some well-characterized potent and selective MAGL 398 
inhibitors by using the classical radiometric assay were not significantly different from the 399 
values calculated with the HPLC-UV method. Moreover, this HPLC-UV assay was 400 
successfully applied to test the mechanism of MAGL inhibition showing that this method is 401 
suitable to assess the reversible/irreversible enzyme-inhibitor interaction and the behaviour of 402 
the compound in relation to the catalytic site and the substrate (competitive/non-competitive). 403 
In addition, we showed that our method is also suitable for testing inhibitors using assay 404 
conditions which resemble the physiological environment of MAGL activity that occurs at 405 
the interface between the cell membrane and the cytosol. As described in the method section, 406 
we used the surfactant Triton® X-100 to form micelles and 4-NPDo as lipophilic MAGL 407 
substrate. Our data showed that in these conditions the enzymatic reaction is more efficient 408 
than using 4-NPA as substrate. On the other hand, the potency of the tested inhibitors 409 
determined by the 4-NPDo/TX method was lower than using the 4-NPA method (in absence 410 
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of Triton® X-100). These results are not totally unexpected since in a similar HPLC-based 411 
method it was already reported that Triton® X-100 reduces the potency of enzyme inhibitors 412 
[34]. This also confirms that inhibition potencies can significantly vary depending on the 413 
assay conditions such as concentration of the substrate, presence of additives, and incubation 414 
time.  415 
The HPLC-UV methods here described are not probably the most suitable format for a 416 
medium/high throughput screening but the use of chromatographic separation of the substrate 417 
(4-NPA or 4-NPDo) and the product (PNP) achieves a high standard of selectivity for the 418 
detection of the analytes with a negligible overlap in the UV measurements. This also 419 
prevents, in an unequivocal manner, any interference related to the intrinsic absorbance of 420 
screened compounds or metabolites generated upon enzymatic cleavage which could affect 421 
the final readout of the assay. This issue is of particular importance when natural products are 422 
tested. Recently, several natural compounds have been identified and characterized as MAGL 423 
inhibitors such as the triterpenes β-amyrin, euphol and pristimerin [36,40,41], with the latter 424 
being the most potent inhibitor with an IC50 value of 93 nM [41]. Pristimerin has an intense 425 
orange-yellow colour with an absorption peak at λ=420 nm and a significant absorption 426 
already at λ=320-340 nm [42]. Therefore, pristimerin interferes strongly or weakly, 427 
depending on the concentration with the quantification of PNP either at λ=405 nm (the 428 
wavelength suggested for the colorimetric quantification assay) or λ=315 nm (the optimal 429 
peak of absorption of PNP). Several classes of molecules and chemical scaffolds possess 430 
intrinsic absorption or fluorescent properties which can seriously affect the quantification of 431 
PNP absorbance. For example, flavonoids consist of a large group of polyphenolic 432 
compounds having a benzo-γ-pyrone structure which are ubiquitously present in plants and 433 
are responsible for the variety of pharmacological activities. Quercetin, kaempferol and 434 
luteoline are among the most studied members of this class of compounds [43]. All three 435 
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molecules show an absorption peak in the range of 250 nm<λ<450 nm, which may interfere 436 
with many absorbance/fluorescence based biological assays. The same issue is present with 437 
diarylheptanoids, of which curcumin is the most important bioactive representative [44]. 438 
Curcumin has a strong intrinsic absorbance with λmax ranging from 400 to 550 nm, depending 439 
of the solvent [45]. Polyphenols are another common natural source of bioactive compounds. 440 
For example, trans-resveratrol has an absorption peak at λ=300-320 nm, leading to potential 441 
alterations of any colorimetric UV-visible detection based assay [46].  442 
By applying the HPLC-UV method, the chromatographic separation of the hydrolytic product 443 
from the substrate and the tested inhibitors avoids any interference in the quantification of the 444 
PNP absorption allowing an accurate, specific and unbiased result.  445 
Finally, the low specificity of 4-NPA as a substrate for esterase could be exploited by our 446 
HPLC-UV method to characterize the effect of compounds not only on MAGL activity, but 447 
also towards the recently identified 2-AG hydrolytic enzymes ABHD-6 and ABHD-12, for 448 
which the pharmacological repertoire of inhibitors is still not satisfying. Only very recently 449 
some compounds have been characterized as selective and potent inhibitors of ABHD-6, such 450 
as the carbamate WWL70 and piperidyl-1,2,3-triazole ureas [5,47], while no potent and 451 
selective inhibitor for ABHD-12 has been described so far.  452 
 453 
5. Conclusion 454 
The developed HPLC assays represent an implemented versions of the “classical” 4-455 
NPA-PNP procedure: indeed the metabolite concentration is determined after 456 
chromatographic separation. This alternative approach allows to obtain an high sensitivity 457 
and to check the activity towards MAGL of compounds/mixture characterized by high 458 
absorbance in the UV-visible range, avoiding the use of radioactive substrate. Therefore these 459 
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methods may represent an helpful tool in the identification/discovery of new natural/synthetic 460 
MAGL inhibitors. 461 
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 619 
Footnotes 620 
 621 
a 4-NPA stability assessed in different solvents, at different temperatures and times of 622 
storage. Values are expressed as % of degraded 4-NPA. 623 
 624 
 625 
b IC50 values of MAGL inhibitors obtained by the classical [
3H]-radiometric-based assay and 626 
the new HPLC-UV-based assay. Values are expressed as mean ± S.D., N= 9 from three 627 
independent experiments. 628 
629 
28 
 
 630 
Tables:  631 
 632 
 633 
 634 
Table 1. Accuracy and precision for PNP 635 
p-nitrophenol 
concentration 
(M) 
Accuracy Precision 
4-NPA 
method 
4-NPDo/TX 
method 
4-NPA method  4-NPDo/TX method 
Within-run Between-run Within-run Between-run 
100 98.1±2.0 96.3±1.2 4.26 2.42 4.31 3.15 
50 101.2±1.3 102.1±1.1 3.91 1.11 3.88 1.21 
0.5 104.9±4.8 106.5±3.2 5.13 4.53 5.22 4.63 
 636 
 637 
 638 
Table 2. 4-NPA stability.a 639 
 
% of degraded 4-NPA after 5 h  % of degraded 4-NPA after 48 h 
 DMSO Ethanol Tris-HCl   DMSO Ethanol Tris-HCl 
r.t. 2 1 60  r.t. 5 6 95 
+3 °C 7 0 53  +3 °C 6 2 91 
-20 °C 0 0 5  -20 °C 3 0 58 
 
 640 
 641 
 642 
Table 3. IC50 values of MAGL inhibitors.
b 643 
Compounds HPLC-UV-based assay 
(nM) 
[3H]-Radiometric-based assay 
(nM) 
JZL184 24.2 ± 1.2  8.1 ± 5.2  
CAY10499 216.0 ± 2.7  157.7 ± 42.9  
JW642 7.43 ± 1.1  9.65 ± 3.5  
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Figures: 649 
 650 
Fig. 1. 651 
 652 
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Fig.2. 671 
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Fig.4.  687 
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Fig. 5. 690 
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Fig. 6. 695 
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 699 
Figure legends: 700 
 701 
Fig 1. Chromatograms of 4-NPA and PNP and of 4-NPDo and PNP at 315 nm performed at 702 
pH = 4. 703 
 704 
Fig 2. UV absorption spectrum of 4-NPA and PNP at pH = 4 (dashed line) and at pH = 7 705 
(solid line) and UV absorption spectrum of 4-NPDo at pH = 4. 706 
 707 
Fig. 3. Influence of different pre-incubation times on JZL184 potency in inhibiting MAGL 708 
activity. JZL184 was assessed at the concentration of 33 nM. Values are expressed as mean ± 709 
S.D., N = 6 from two independent experiments  710 
 711 
Fig. 4. Inhibition of hrMAGL activity by selective MAGL inhibitors (JZL184, CAY10499 712 
and JW642) and negative controls (URB597 and WWL70). All the inhibitors were tested at 713 
the concentration of 1 µM. Values are expressed as mean ± S.D, N = 9 from three 714 
independent experiments. 715 
 716 
Fig. 5. Reversibility of hrMAGL inhibition by JZL184. Rapid dilution assay of hrMAGL in 717 
the presence of JZL184 or vehicle. Results are expressed as amount of product generated 718 
(expressed as concentration). Values are expressed as mean ± S.D., N = 6 from two 719 
independent experiments.  720 
 721 
Fig. 6. Michaelis-Menten analysis of hrMAGL reaction. Enzymatic activity was measured as 722 
µg min-1 mg-1 protein in the presence of vehicle (circles) or JZL184 33 nM (squares). Values 723 
are expressed as mean ± S.D., N = 6 from two independent experiments.  724 
 725 
 726 
